HK1077830A1 - Crystals of glucopyranosyloxybenzyl benzene derivative - Google Patents

Crystals of glucopyranosyloxybenzyl benzene derivative

Info

Publication number
HK1077830A1
HK1077830A1 HK05109901A HK05109901A HK1077830A1 HK 1077830 A1 HK1077830 A1 HK 1077830A1 HK 05109901 A HK05109901 A HK 05109901A HK 05109901 A HK05109901 A HK 05109901A HK 1077830 A1 HK1077830 A1 HK 1077830A1
Authority
HK
Hong Kong
Prior art keywords
crystals
benzene derivative
glucopyranosyloxybenzyl
glucopyranosyloxybenzyl benzene
derivative
Prior art date
Application number
HK05109901A
Other languages
English (en)
Inventor
Akira Iyobe
Hirotaka Teranishi
Kazuya Tatani
Shigeru Yonekubo
Masayuki Isaji
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of HK1077830A1 publication Critical patent/HK1077830A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK05109901A 2002-03-22 2005-11-07 Crystals of glucopyranosyloxybenzyl benzene derivative HK1077830A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002081038 2002-03-22
PCT/JP2003/002466 WO2003080635A1 (fr) 2002-03-22 2003-03-04 Cristaux de derive de glucopyranosyloxybenzylbenzene

Publications (1)

Publication Number Publication Date
HK1077830A1 true HK1077830A1 (en) 2006-02-24

Family

ID=28449107

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05109901A HK1077830A1 (en) 2002-03-22 2005-11-07 Crystals of glucopyranosyloxybenzyl benzene derivative

Country Status (14)

Country Link
US (1) US7371730B2 (es)
EP (1) EP1489089A4 (es)
JP (1) JP4490109B2 (es)
KR (1) KR100945455B1 (es)
CN (1) CN1307190C (es)
AU (1) AU2003211543B2 (es)
BR (1) BR0308653A (es)
CA (1) CA2476800C (es)
HK (1) HK1077830A1 (es)
MX (1) MXPA04009229A (es)
NO (1) NO330297B1 (es)
NZ (1) NZ535230A (es)
PL (1) PL210710B1 (es)
WO (1) WO2003080635A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4490109B2 (ja) 2002-03-22 2010-06-23 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体の結晶
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2725047A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
TWI441831B (zh) 2008-08-22 2014-06-21 Theracos Inc 製備sglt2抑制劑之方法
AU2009286380B2 (en) * 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
SG173619A1 (en) 2009-02-13 2011-09-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US8420819B2 (en) * 2009-06-03 2013-04-16 Boehringer Ingelheim International Gmbh Process for optimizing the particle size of an active pharmaceutical ingredient by crystallization
ES2527179T3 (es) 2009-11-02 2015-01-21 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
EP2552442A1 (en) 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2714052B1 (en) 2011-06-03 2018-09-19 Boehringer Ingelheim International GmbH Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
EP4245765A3 (en) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
DK3082829T3 (da) 2013-12-17 2021-05-03 Boehringer Ingelheim Vetmedica Gmbh Sglt2-inhibitorer til behandlingen af metaboliske lidelser i kattedyr
LT3485890T (lt) 2014-01-23 2023-07-25 Boehringer Ingelheim Vetmedica Gmbh Sglt2 inhibitoriai, skirti šuninių gyvūnų medžiagų apykaitos sutrikimų gydymui
MX2016012705A (es) 2014-04-01 2016-12-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales equinos.
US20210212968A1 (en) 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
AU2019254371A1 (en) 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EA202190226A1 (ru) 2018-07-19 2021-06-16 Астразенека Аб СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2022006490A (es) 2019-11-28 2022-07-04 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamiferos no humanos.
EP4106744A1 (en) 2020-02-17 2022-12-28 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
EP4315350A1 (en) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN117715640A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物,特别是犬科动物中预防和/或治疗心脏疾病的用途
CA3224673A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1270584B1 (en) 2000-03-17 2005-12-07 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
WO2002028872A1 (fr) * 2000-09-29 2002-04-11 Kissei Pharmaceutical Co., Ltd. Derives de glucopyranosiloxybenzylbenzene et compositions therapeutiques contenant ces composes
JP4490109B2 (ja) 2002-03-22 2010-06-23 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体の結晶

Also Published As

Publication number Publication date
KR20040099347A (ko) 2004-11-26
PL210710B1 (pl) 2012-02-29
AU2003211543B2 (en) 2009-03-12
US7371730B2 (en) 2008-05-13
NZ535230A (en) 2006-10-27
BR0308653A (pt) 2005-02-15
EP1489089A1 (en) 2004-12-22
KR100945455B1 (ko) 2010-03-05
JP4490109B2 (ja) 2010-06-23
NO330297B1 (no) 2011-03-21
CA2476800C (en) 2010-08-17
JPWO2003080635A1 (ja) 2005-07-21
MXPA04009229A (es) 2004-11-26
CN1307190C (zh) 2007-03-28
PL372415A1 (en) 2005-07-25
US20050119192A1 (en) 2005-06-02
NO20044426L (no) 2004-12-22
WO2003080635A1 (fr) 2003-10-02
EP1489089A4 (en) 2009-10-28
AU2003211543A1 (en) 2003-10-08
CN1642965A (zh) 2005-07-20
CA2476800A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
HK1077830A1 (en) Crystals of glucopyranosyloxybenzyl benzene derivative
IL166202A0 (en) Azolidinone-vinyl benzene derivatives
GB0212412D0 (en) Combination of organic compounds
PL372369A1 (en) Combination of organic compounds
HK1082497A1 (en) Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
HUS1400037I1 (hu) Új 2-piridiletilbenzamid származékok
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
EP1537102A4 (en) INHIBITORS OF PHOSPHOINOSITIDE-3-KINASE BETA
SI2932981T1 (sl) Albumin-vezavni derivati GLP-1
HK1084043A1 (en) Derivatives of aryl-quinazoline/aryl-2amino-phenylmethanone which promote the release of parathyroidhormone
EP1485335A4 (en) PRODUCTION OF ALKYL AROMATIC COMPOUNDS
EG23458A (en) Set of elements for assemlying structures
ZA200500294B (en) Novel 2-pyridylethylbenzamide derivative
AU2002330453A1 (en) Crystals of hydroxynorephedrine derivative
AP1955A (en) Novel crystalline modification of the anhydrate ofboscalid
AU2003202281A1 (en) Mixtures of quaternary compounds
AU2003268687A1 (en) Novel salt of 2-acylaminothiazole derivative
TWI367754B (en) New carboxamide compound
EP1572950A3 (en) Single domain tdf-related compounds and analogs thereof
EP1572950A4 (en) SINGLE-DOMAIN-TDF-RELATED CONNECTIONS AND ANALOGS OF IT
AU2003246963A8 (en) Synthesis of cyclohexanone derivatives
AU2003282510A8 (en) Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
GB0207623D0 (en) Crystal structure of g-quadruplex
EP1486485A4 (en) NEW 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE CRYSTALS
AU2003262141A8 (en) Preperation of desloratatine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120304